Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments.

Nakhjavani, Maryam; Smith, Eric; Yeo, Kenny; Palethorpe, Helen M; Tomita, Yoko; Price, Tim J; Townsend, Amanda R; Hardingham, Jennifer E

Nakhjavani, Maryam; Smith, Eric; Yeo, Kenny; Palethorpe, Helen M; Tomita, Yoko; Price, Tim J; Townsend, Amanda R; Hardingham, Jennifer E.

Afiliação

Nakhjavani M; Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia.
Smith E; Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia.
Yeo K; Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia.
Palethorpe HM; Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia.
Tomita Y; Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia.
Price TJ; Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia.
Townsend AR; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia.
Hardingham JE; Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia.

Cancers (Basel) ; 13(9)2021 May 06.

Article em En | MEDLINE | ID: mdl-34066403

Palavras-chave

angiogenesis; epimer; ginsenoside Rg3; optimisation; response surface methodology

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália